Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEITHO-2: LMWH for 72 hours followed by dabigatran in acute intermediate-risk pulmonary embolism
NL-OMON45434Phase 4Active, not recruiting
- Sponsor
- University Medical Center Mainz
- Start
- Sep 2017
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dabigatran and low molecular weight heparin calcium in pulmonary embolism (PE), sponsored by University Medical Center Mainz. Primary endpoint: Primary efficacy and safety outcome. Started Sep 2017; status: active, not recruiting.
02
Drugs
dabigatranlow molecular weight heparin calcium
03
Conditions
pulmonary embolism (PE)
Beyond the preview
Go deeper on NL-OMON45434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45434.